Post-transplant Lymphoproliferative Disorder
📧 Sign up to get email alerts when something new happens for Post-transplant Lymphoproliferative Disorder.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2026-04-21Clinical Trial Update: BZLF1 Peptide Vaccine (OSU-2131) With QS-21 for the Prevention of Epstein-Barr Virus Related Cancer in Patients Awaiting Solid Organ Transplants [Phase 1]
Phase 1 trial of the BZLF1 peptide vaccine OSU-2131 with QS-21 to prevent Epstein-Barr virus–related cancers in patients awaiting solid orga…
-
CLINICAL_TRIALS research · 2026-02-27Clinical Trial Update: EBV-AST Cell Therapy for EBV-Related Diseases After Stem Cell Transplantation [Phase 1, Phase 2]
A Phase 1/2 clinical trial evaluating EBV-AST cell therapy for Epstein-Barr virus-related diseases after stem cell transplantation, currentl…
-
CLINICAL_TRIALS research · 2026-02-20Clinical Trial Update: A Phase 3 Study of Tabelecleucel for Participants With Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease After Failure With Rituximab or Rituximab and Chemotherapy [Phase 3]
Phase 3 study evaluating Tabelecleucel for Epstein-Barr virus-associated post-transplant lymphoproliferative disorder in patients after ritu…
-
CLINICAL_TRIALS research · 2026-02-17Clinical Trial Update: Epcoritamab and Lenalidomide in Treating Patients With Refractory or Relapsed Immunodeficiency-Related Large B-Cell Lymphoma [Phase 2]
A Phase 2 trial update from Northwestern University evaluating the combination of epcoritamab and lenalidomide in patients with refractory o…
-
CLINICAL_TRIALS research · 2026-01-28Clinical Trial Update: Exploratory Study of EBV-TCR-T Cell Injection for EBV DNAemia After Allogeneic Hematopoietic Stem Cell Transplantation [Phase 1, Phase 2]
This clinical trial update describes an exploratory study of EBV-TCR-T cell therapy to treat EBV DNAemia after allogeneic hematopoietic stem…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2026-01-15Clinical Trial Update: Reduced Immunosuppressive Therapy With or Without Donor White Blood Cells in Treating Patients With Lymphoproliferative Disease After Organ Transplantation [Phase 3]
A Phase 3 trial evaluating reduced immunosuppressive therapy with or without donor white blood cells in patients with post-transplant lympho…
-
CLINICAL_TRIALS research · 2025-12-04Clinical Trial Update: A Prospective Study to Evaluate the Role of T-Cell Dysfunction in Patients Who Present Symptoms Associated With Long COVID, Lyme Disease and Myalic Encephalomyelitis / Chronic Fatigue Syndrome Using the Vira Immune Fluorospot T Cell Assay
A prospective study sponsored by ViraxBio Labs is evaluating T-cell dysfunction in patients with Long COVID, post-transplant lymphoprolifera…
-
CLINICAL_TRIALS research · 2025-12-02Clinical Trial Update: PTLD: Multicentric Retrospective Study
A multicenter retrospective study evaluating post-transplant lymphoproliferative disorder (PTLD) is active but not recruiting participants.
-
CLINICAL_TRIALS trial_result · 2025-11-20Clinical Trial Update: EVITA Study - Epstein-Barr Virus Infection moniToring in renAl Transplant Recipients
EVITA is a completed study monitoring Epstein-Barr virus infection in renal transplant recipients; the snippet does not include trial result…
-
CLINICAL_TRIALS research · 2025-10-28Clinical Trial Update: Polatuzumab Vedotin (Pola) Plus Rituximab (R) in Patients With Post-transplant Lymphoproliferative Disorder (PTLD) [Phase 1, Phase 2]
This Phase 1/2 clinical trial is evaluating the combination of polatuzumab vedotin with rituximab for post-transplant lymphoproliferative di…
-
CLINICAL_TRIALS research · 2025-10-16Clinical Trial Update: Loncastuximab Tesirine for the Treatment of Relapsed or Refractory B-Cell Malignancies [Phase 2]
This update reports a Phase 2 trial of loncastuximab tesirine for relapsed or refractory B-cell malignancies that is currently recruiting, i…
-
CLINICAL_TRIALS trial_result · 2025-10-14Clinical Trial Update: Dose Adjusted EPOCH-R, to Treat Mature B Cell Malignancies [EARLY_Phase 1]
The document summarizes a Phase 1 trial of dose-adjusted EPOCH-R for mature B-cell malignancies, including Diffuse Large B-Cell Lymphoma, Po…
-
CLINICAL_TRIALS research · 2025-08-19Clinical Trial Update: Epcoritamab for the Treatment of Relapsed or Refractory Post Transplant Lymphoproliferative Disorders [Phase 1]
Phase 1 trial update for Epcoritamab in relapsed or refractory post-transplant lymphoproliferative disorders, including DLBCL-type PTLD and …
-
CLINICAL_TRIALS trial_result · 2025-07-28Clinical Trial Update: An Open-Label Phase 2 Trial of Nanatinostat Plus Valganciclovir in Patients With EBV+ Relapsed/Refractory Lymphomas [Phase 2]
An open-label Phase 2 trial evaluating nanatinostat plus valganciclovir in EBV-positive relapsed/refractory lymphomas has been terminated, w…
-
CLINICAL_TRIALS trial_result · 2025-05-14Clinical Trial Update: A Study of the Safety and Efficacy of EBV Specific T-cell Lines [Phase 1, Phase 2]
A completed Phase 1/2 study evaluated the safety and efficacy of Epstein-Barr virus–specific T-cell lines in patients with Epstein-Barr viru…
-
CLINICAL_TRIALS research · 2025-05-02Clinical Trial Update: Defining ctDNA Metrics in Posttransplant Lymphoproliferative Disorder (PTLD) [Phase 2]
Phase 2 clinical trial update exploring circulating tumor DNA (ctDNA) metrics in posttransplant lymphoproliferative disorder (PTLD).
-
CLINICAL_TRIALS research · 2025-03-03Clinical Trial Update: EBV-Tscm Cytotoxic T Cells (CTLs) for EBV- Driven Lymphomas/ Diseases [Phase 1, Phase 2]
This document provides an update on an early-stage study of EBV-Tscm cytotoxic T cells for Epstein-Barr virus–driven lymphomas and post-tran…
-
CLINICAL_TRIALS research · 2024-08-19Clinical Trial Update: Evaluation of the Efficacy of a Treatment by One Single Dose of Rituximab (375mg/m2 ) in the Prevention of the Epstein Barr Virus (EBV) Primary Infection and Post-transplant Lymphoproliferative Disorder in Adult EBV Seronegative Patients Who Received an EBV Seropositive Kidney Allograft [Phase 4]
A Phase 4 clinical trial is evaluating whether a single dose of rituximab (375 mg/m2) can prevent Epstein-Barr virus infection and post-tran…
-
CLINICAL_TRIALS research · 2024-07-10Clinical Trial Update: Whole-body Diffusion-weighted Magnetic Resonance Imaging for Staging and Treatment Prediction of Lymphoma [NA]
This document provides an update on a clinical trial evaluating whole-body diffusion-weighted MRI for staging and predicting treatment respo…
-
CLINICAL_TRIALS research · 2024-05-17Clinical Trial Update: Immunotherapy With Tacrolimus Resistant EBV CTL for Lymphoproliferative Disease After Solid Organ Transplant [EARLY_Phase 1]
An early-phase 1 trial is evaluating tacrolimus-resistant EBV-specific cytotoxic T lymphocytes for post-transplant lymphoproliferative disor…
-
CLINICAL_TRIALS trial_result · 2024-04-10Clinical Trial Update: Rituximab and Acalabrutinib in Newly Diagnosed B Cell Post Transplant Lymphoproliferative Disorder [Phase 2]
Phase 2 trial evaluating rituximab and acalabrutinib in newly diagnosed post-transplant lymphoproliferative disorder was terminated with res…
-
CLINICAL_TRIALS trial_result · 2022-08-02Clinical Trial Update: Ex-vivo Delivery of Rituximab to Prevent PTLD in EBV Mismatch Lung Transplant Recipients: A Pilot Trial [Phase 1, Phase 2]
Pilot trial investigating ex-vivo delivery of rituximab to prevent PTLD in EBV mismatch lung transplant recipients; Phase 1/2 study with unk…
-
CLINICAL_TRIALS trial_result · 2022-06-03Clinical Trial Update: Rituximab and LMP-Specific T-Cells in Treating Pediatric Solid Organ Recipients With EBV-Positive, CD20-Positive Post-Transplant Lymphoproliferative Disorder [Phase 2]
Phase 2 trial evaluating the combination of rituximab and LMP-specific T cells for EBV-positive, CD20-positive post-transplant lymphoprolife…
-
CLINICAL_TRIALS trial_result · 2021-05-25Clinical Trial Update: High-Dose Y-90-Ibritumomab Tiuxetan Added to Reduced-Intensity Allogeneic Stem Cell Transplant Regimen for Relapsed or Refractory Aggressive B-Cell Lymphoma [Phase 2]
Phase 2 trial evaluating high-dose Y-90 ibritumomab tiuxetan added to reduced-intensity allogeneic stem cell transplant for relapsed or refr…
-
CLINICAL_TRIALS trial_result · 2020-03-23Clinical Trial Update: Everolimus and Lenalidomide in Treating Patients With Relapsed or Refractory Non-Hodgkin or Hodgkin Lymphoma [Phase 1, Phase 2]
Phase 1/2 trial evaluating everolimus and lenalidomide in relapsed or refractory non-Hodgkin or Hodgkin lymphoma; results posted.